نتایج جستجو برای: cytarabine

تعداد نتایج: 4434  

Journal: :Leukemia research 2012
Josy S Naud Karim Ghani Pedro O de Campos-Lima Manuel Caruso

The tyrosine kinase inhibitor (TKI) imatinib has been used for a decade to treat chronic myeloid leukemia (CML). A very efficient response is obtained with patients in chronic phase, but its efficacy in late phase patients is often transient. The combination of imatinib or of the new TKI nilotinib with cytarabine is a new treatment approach proposed for CML. We have investigated the effect of i...

Journal: :Blood 2005
Ruben A Mesa David Loegering Heather L Powell Karen Flatten Sonnet J H Arlander Nga T Dai Michael P Heldebrant Benjamin T Vroman B Douglas Smith Judith E Karp Cynthia J Ten Eyck Charles Erlichman Scott H Kaufmann Larry M Karnitz

Previous studies demonstrated that ataxia telangiectasia mutated- and Rad3-related (ATR) kinase and its downstream target checkpoint kinase 1 (Chk1) facilitate survival of cells treated with nucleoside analogs and other replication inhibitors. Recent results also demonstrated that Chk1 is depleted when cells are treated with heat shock protein 90 (Hsp90) inhibitor 17-allylamino-17-demethoxygeld...

Journal: :Pediatrics 2016
Daniel Tibussek Rungrote Natesirinilkul Lisa R Sun Bruce A Wasserman Leonardo R Brandão Gabrielle deVeber

We report on 2 patients who developed widespread cerebral vasospasm and arterial ischemic strokes (AIS) after application of intrathecal (IT) cytarabine. In a 3-year-old child with acute lymphoblastic leukemia (ALL), left leg weakness, hyperreflexia, and clonus were noted 4 days after her first dose of IT cytarabine during the induction phase of her chemotherapy. Cerebral MRI revealed multiple ...

Journal: :Blood 2013
Eric R Gamazon Jatinder K Lamba Stanley Pounds Amy L Stark Heather E Wheeler Xueyuan Cao Hae K Im Amit K Mitra Jeffrey E Rubnitz Raul C Ribeiro Susana Raimondi Dario Campana Kristine R Crews Shan S Wong Marleen Welsh Imge Hulur Lidija Gorsic Christine M Hartford Wei Zhang Nancy J Cox M Eileen Dolan

A whole-genome approach was used to investigate the genetic determinants of cytarabine-induced cytotoxicity. We performed a meta-analysis of genome-wide association studies involving 523 lymphoblastoid cell lines (LCLs) from individuals of European, African, Asian, and African American ancestry. Several of the highest-ranked single-nucleotide polymorphisms (SNPs) were within the mutated in colo...

Journal: :Blood 2000
M S Tallman P A Rowlings G Milone M J Zhang W S Perez D Weisdorf A Keating R P Gale R B Geller M J Laughlin H M Lazarus S M Luger P L McCarthy J M Rowe R A Saez M R Vowels M M Horowitz

Allogeneic bone marrow transplantation is an effective postremission strategy for patients with acute myelogenous leukemia (AML) in first complete remission (CR). The value of administering consolidation chemotherapy before human leukocyte antigen (HLA)-identical sibling transplantation is not established. Outcomes of patients with AML in first CR receiving no consolidation therapy, standard-do...

Journal: :Blood 1988
W Gassmann L Uharek H U Wottge N Schmitz H Löffler W Mueller-Ruchholtz

Etoposide and cytarabine have been shown to exert high antileukemic activity and are currently under study as preparatory agents before allogeneic bone marrow transplantation. However, data concerning their engraftment-promoting potency are scarce. Therefore, we tested these agents in LEW rats receiving a myeloablative dose of busulfan followed by transfer of F1 (CAP X LEW) marrow, which is una...

Journal: :Pediatric blood & cancer 2013
Katrine Helle Johannsen Mette Møller Handrup Birgitte Lausen Henrik Schrøder Henrik Hasle

BACKGROUND High-dose cytarabine has been associated with a high frequency of viridans group streptococcal (VGS) bacteraemia. VGS bacteraemia causes considerable morbidity and mortality. The Nordic Society of Paediatric Haematology and Oncology (NOPHO)-AML protocols use higher cumulated doses of cytarabine and more chemotherapy series (n = 6) than other protocols with the potential increased ris...

Journal: :Leukemia research 2016
Giorgia Montano Tove Ullmark Helena Jernmark-Nilsson Gaetano Sodaro Kristina Drott Paola Costanzo Karina Vidovic Urban Gullberg

The transcription factor interferon regulatory factor-8 (IRF8) is highly expressed in myeloid progenitors, while most myeloid leukemias show low or absent expression. Loss of IRF8 in mice leads to a myeloproliferative disorder, indicating a tumor-suppressive role of IRF8. The Wilms tumor gene 1 (WT1) protein represses the IRF8-promoter. The zinc finger protein ZNF224 can act as a transcriptiona...

2013
Chengzhi Xie Christina Drenberg Holly Edwards J. Timothy Caldwell Wei Chen Hiroto Inaba Xuelian Xu Steven A. Buck Jeffrey W. Taub Sharyn D. Baker Yubin Ge

Acute myeloid leukemia (AML) remains a challenging disease to treat and urgently requires new therapies to improve its treatment outcome. In this study, we investigated the molecular mechanisms underlying the cooperative antileukemic activities of panobinostat and cytarabine or daunorubicin (DNR) in AML cell lines and diagnostic blast samples in vitro and in vivo. Panobinostat suppressed expres...

Journal: :Blood 2007
Carolyn Blasdel Merrill J Egorin Theodore F Lagattuta Brian J Druker Michael W Deininger

each, although toxicities were not directly attributed to the agent.2 In their letter, Chamberlain and Glantz comment on the neurologic syndromes we reported and question attribution to liposomal cytarabine. Our attributions were based on 15-year experience in nearly 500 adults with acute lymphoblastic leukemia without central nervous system (CNS) disease, treated with hyperCVAD (cyclophosphami...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید